Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05509595 |
Recruitment Status :
Active, not recruiting
First Posted : August 22, 2022
Last Update Posted : March 19, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Fibrous dysplasia (FD) is a disorder that affects bone growth. Affected bone tissue is weakened, and people with FD are prone to deformities, fractures, and other problems. People with FD may also have low blood phosphate levels. This can make bones even weaker. Better treatments are needed.
Objective:
To test a study drug (burosumab) in people with FD who have low blood phosphate levels.
Eligibility:
People aged 1 year or older who have FD and low blood phosphate levels.
Design:
Participants will visit the NIH 3 times in 48 weeks. Each visit will last 5 to 7 days.
Participants will self-inject burosumab under the skin in their belly, upper arm, or thigh. They (or a caregiver) will do this at home 1 or 2 times a month. They will be trained in person on how to inject the drug. Home injections will be guided via telehealth.
During NIH visits, participants will have a physical exam with blood and urine tests. They will have x-rays of different parts of their body. They will have a radioactive tracer injected into their vein; then they will have a bone scan. They will have tests to assess their strength, walking, and movement. They will complete questionnaires about their pain, mobility, and fatigue levels.
Adult participants may have bone biopsies. These will be done under anesthesia with sedation. Small samples of FD-affected bone will be removed for study.
Between NIH visits, participants will go to a local laboratory for blood and urine tests.
Child participants will have an additional follow-up visit 2 weeks after the final NIH visit.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibrous Dysplasia Of Bone | Drug: Burosumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Study of Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia |
Actual Study Start Date : | December 7, 2022 |
Estimated Primary Completion Date : | September 30, 2030 |
Estimated Study Completion Date : | September 30, 2030 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment
Patients receiving treatment
|
Drug: Burosumab
Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23) |
- The proportion of subjects achieving serum phosphate levels within the target range (Z-score -1 to +2) at Week 48 [ Time Frame: 48 weeks ]Serum phosphate is the primary driver of skeletal complications in patients with FGF23-mediated hypophosphatemia and has been correlated with poor clinical outcomes in patients with FD.
- Change and percent change from baseline to post-baseline visits in serum phosphate, serum 1,25(OH)2D, ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR). [ Time Frame: 48 weeks ]Safety endpoint for monitoring metabolic impact of burosumab in patients with FD.
- Change in functional parameters: - Muscle strength - Range-of-motion - Walking speed (9-minute walk) [ Time Frame: 48 weeks ]Outcome measures that reflect activities of daily living
- Change in FD lesion histology and cell proliferation as assessed by minimally invasive bone biopsies from baseline to 48 weeks (adults with capacity to consent only) from baseline to 48 weeks [ Time Frame: 48 weeks ]Safety endpoints to determine if burosumab impacts metabolic activity of FD lesions, which are a benign neoplastic process
- Change from baseline to 48 weeks in patient reported outcomes measures: SF36, SF10, Brief Fatigue Inventory [ Time Frame: 48 weeks ]Outcome measures to determine pain and health-related quality of life
- Proportion of subjects achieving serum phosphate levels within the target range (Z-score -1 to +2) at Week 24. [ Time Frame: 24 weeks ]Serum phosphate is the primary driver of skeletal complications in patients with FGF23-mediated hypophosphatemia and has been correlated with poor clinical outcomes in patients with FD.
- Change and percent change in serum bone turnover markers, including procollagen 1 N-terminal propeptide (P1NP), beta crosslaps C-telopeptides (CTX), osteocalcin, and bone-specific alkaline phosphatase from baseline to 48 weeks. [ Time Frame: 48 weeks ]Safety endpoints to determine if burosumab impacts metabolic activity of FD lesions, which are a benign neoplastic process
- Adverse events and clinical safety laboratory tests for up to 4 weeks after the final burosumab dose [ Time Frame: 48 weeks (adults), 50 weeks (children) ]Safety endpoints for expected and unexpected adverse events
- Change in FD lesion activity using 18F-NaF PET/CT total lesion activity [ Time Frame: 48 weeks ]Safety endpoints to determine if burosumab impacts metabolic activity of FD lesions, which are a benign neoplastic process
- Skeletal changes assessed on skeletal survey at baseline and 48 weeks [ Time Frame: 48 weeks ]Safety endpoints to determine if burosumab impacts metabolic activity of FD lesions, which are a benign neoplastic process
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 99 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Confirmed diagnosis of fibrous dysplasia
- Serum phosphate <10th percentile for age and sex, AND intact serum FGF23 >=30 pg/mL
- Age >=1 year
- Provision of signed and dated informed consent/assent form
- Stated willingness of subject or Legally Authorized Representative (LAR) to comply with all study procedures and availability for the duration of the study
-
For females of reproductive potential: agreement to use highly effective contraception for during study participation. Highly effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment.
- Male sterilization (at least 6 months prior to screening). For female participants on the study the vasectomized male partner should be the sole partner for that participant.
-
Combination of the following (a+b or a+c, or b+c):
- Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
- Placement of an intrauterine device (IUD) or intrauterine system (IUS)
- Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
- For males of reproductive potential: use of condoms or other methods described above to ensure effective contraception with partner
- Minimum body weight of 7.5 kilograms
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy or lactation
- Known allergic reactions to burosumab or drug component
- Treatment with another investigational drug within 30 days of screening
- Treatment with burosumab within 30 days of screening
- Have any condition which in the opinion of the PI could present a concern for subject safety or difficulty with data interpretation
- Severe renal impairment or end stage renal disease, defined as: pediatric patients with estimated glomerular filtration rate (eGFR) 15 mL/min/1.73m2 to 29 mL/min/1.73m2 or end stage renal disease (eGFR < 15 mL/min/1.73m2), adult patients with creatinine clearance (CLcr) 15 mL/min to 29 mL/min or end stage renal disease (CLcr < 15 mL/min)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05509595
United States, Maryland | |
National Institutes of Health Clinical Center | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Alison M Boyce, M.D. | National Institute of Dental and Craniofacial Research (NIDCR) |
Responsible Party: | National Institute of Dental and Craniofacial Research (NIDCR) |
ClinicalTrials.gov Identifier: | NCT05509595 |
Other Study ID Numbers: |
10000798 000798-D |
First Posted: | August 22, 2022 Key Record Dates |
Last Update Posted: | March 19, 2024 |
Last Verified: | March 15, 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | .The study team anticipates that all IPD that underlie results in a publication will be made available on reasonable request. The specifics of the timing and review process are in development. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
McCune-Albright Syndrome Rickets Osteomalacia Metabolic Bone Disorders |
Fibrous Dysplasia of Bone Hypophosphatemia Phosphorus Metabolism Disorders Metabolic Diseases |
Osteochondrodysplasias Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases |